The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma. Read More >>
targeted therapy
June 3, 2022 · Greg Guthrie, ASCO staff
February 3, 2022 · Brielle Gregory Collins, ASCO staff
In this podcast, Dr. Christopher Flowers discusses research from the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, including studies evaluating new treatments for diffuse large B-cell lymphoma and an overview of a session on improving equity in cancer clinical trials. Read More >>
January 24, 2022 · Brielle Gregory Collins, ASCO staff
Read research from the January 2022 session of the ASCO Plenary Series, which highlights a study comparing 2 targeted therapies in treating advanced gastrointestinal stromal tumors (GISTs). Read More >>
December 29, 2021 · Frank Sierawski, as told to Jo Cavallo
Stage IV lung cancer survivor Frank Sierawski shares what it was like being diagnosed with cancer at age 35 and how he learned to cope with the diagnosis by living in the moment. Read More >>
December 16, 2021 · Brielle Gregory Collins, ASCO staff
In this podcast, 4 experts discuss the first-ever targeted therapies approved for people with non-small cell lung cancer with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation, including how they work and what they mean for people with this type of cancer. Read More >>